Indivior's all-stock merger with Supernus would create a $2.2 billion CNS pharmaceutical company, cutting reliance on its flagship Sublocade franchise.
Back
Indivior, Supernus $2.2B merger broadens CNS portfolio
Indivior's all-stock merger with Supernus would create a $2.2 billion CNS pharmaceutical company, cutting reliance on its flagship Sublocade franchise.
Indivior agreed to merge with Supernus in a tax-free, all-stock transaction that would create a $2.2 billion central nervous system-focused pharmaceutical company, while separately beating second-quarter earnings estimates and raising full-year guidance.
The combined entity will trade on Nasdaq under the ticker SUPN, with Indivior shareholders owning 56.5 percent of the merged company and Supernus shareholders holding 43.5 percent, according to the definitive merger agreement announced by both companies.
Indivior reported adjusted earnings of $1.15 per share for the second quarter, up 125.5 percent year over year and beating the consensus estimate of 97 cents. Total revenues rose 13.6 percent to $343 million, driven by record U.S. Sublocade net revenues of $238 million, up 22 percent. The company raised its full-year revenue guidance to $1.295-$1.365 billion from $1.215-$1.285 billion.
The merger would diversify Indivior's revenue base beyond Sublocade, which generated roughly 74 percent of quarterly revenue, while delivering $125 million in annual cost savings. The transaction is expected to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals.
The proposed merger integrates Indivior's addiction medicine franchise with Supernus' broader CNS expertise across psychiatry and neurology. The combined company will market 11 medicines spanning these therapeutic areas, with pro forma annual revenues of approximately $2.2 billion and adjusted EBITDA of $888 million.
Sublocade, Indivior's long-acting injectable for opioid use disorder, delivered a quarterly record of $253 million in net revenues, up 21 percent year over year. U.S. dispense unit volume grew 18 percent, with roughly 32,816 new patient starts during the quarter. More than 545,000 U.S. patients have been prescribed Sublocade since launch. U.S. sublingual and other product revenues rose to $57 million from $52 million a year earlier, while Perseris revenues declined to $5 million from $8 million. Rest of World revenues fell 6.5 percent to $43 million.
Guidance Up, But Shares Slip
Despite the earnings beat and raised outlook, INDV shares fell 6.6 percent on the merger announcement. Year to date, the stock has gained 4.1 percent against the industry's 4.4 percent decline.
Indivior lifted its total Sublocade net revenue forecast to $1.01-$1.05 billion from $950-$990 million, implying approximately 20 percent year-over-year growth at the midpoint. Adjusted EBITDA guidance was raised to $700-$740 million from $620-$660 million. The adjusted operating expense outlook was maintained at $430-$450 million.
The company's cost discipline drove adjusted operating expenses down 33 percent year over year to $112 million, while adjusted EBITDA surged 111 percent to $186 million. Overall U.S. revenues rose to $300 million from $256 million a year earlier. Indivior ended the quarter with $249 million in cash and investments, up from $201 million at the end of March, and repurchased about 4.7 million shares for $175 million at an average price of $37.52.
Deal Risks and Timeline
The merger faces shareholder and regulatory approvals, with closing targeted for the fourth quarter of 2026. The combined company will be headquartered at Supernus' existing site. The all-stock structure means both shareholder bases will share in the combined entity's upside and downside.
For Indivior, the merger reduces concentration risk tied to Sublocade, which generated roughly 74 percent of total quarterly revenue. For Supernus, the deal adds Indivior's addiction medicine franchise to its existing portfolio of CNS treatments.
The combined company plans to advance Supernus' pipeline programs while pursuing additional business development opportunities to expand its CNS portfolio further. Peer companies in the CNS space include Harmony Biosciences and Liquidia Corporation, both carrying Zacks Rank #1 (Strong Buy) ratings. Harmony Biosciences has seen 2026 EPS estimates decline from $3.34 to $3.30 over the past 90 days, while Liquidia's 2026 estimates have risen from $1.50 to $3.02.
This article is for informational purposes only and does not constitute investment advice.
